WEKO3
アイテム
Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser1177/Thr497 of endothelial nitric oxide synthase in diabetic mice
https://tokushima-u.repo.nii.ac.jp/records/2000297
https://tokushima-u.repo.nii.ac.jp/records/200029780144d71-d099-4fe5-b975-32940c71a11e
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
cardiab_13_30.pdf (639 KB)
|
https://creativecommons.org/licenses/by/2.0
|
| Item type | 文献 / Documents(1) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-02-20 | |||||||||||||||||||||||
| アクセス権 | ||||||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||
| 出版社版DOI | ||||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.1186/1475-2840-13-30 | |||||||||||||||||||||||
| 言語 | ja | |||||||||||||||||||||||
| 関連名称 | 10.1186/1475-2840-13-30 | |||||||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||
| タイトル | Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser1177/Thr497 of endothelial nitric oxide synthase in diabetic mice | |||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 著者 |
Matsumoto, Sachiko
× Matsumoto, Sachiko
× 島袋, 充生× 福田, 大受× 添木, 武
WEKO
183
× Yamakawa, Ken
× Masuzaki, Hiroaki
× 佐田, 政隆
WEKO
309
|
|||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||
| 内容記述 | Background: Azilsartan, an angiotensin II type 1 (AT1) receptor blocker (ARB), has a higher affinity for and slower dissociation from AT1 receptors and shows stronger inverse agonism compared to other ARBs. Possible benefits of azilsartan in diabetic vascular dysfunction have not been established. Methods: We measured vascular reactivity of aortic rings in male KKAy diabetic mice treated with vehicle, 0.005% azilsartan, or 0.005% candesartan cilexetil for 3 weeks. Expression of markers of inflammation and oxidative stress was measured using semiquantitative RT-PCR in the vascular wall, perivascular fat, and skeletal muscle. Phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser1177 and Thr495 was measured using Western blotting, and the ratio of phosphorylation at Ser1177 to phosphorylation at Thr495 was used as a putative indicator of vascular eNOS activity. Results: (1) Vascular endothelium–dependent relaxation with acetylcholine in KKAy mice was improved by azilsartan treatment compared to candesartan cilexetil; (2) the ratio of Ser1177/Thr495 phosphorylation of eNOS was impaired in KKAy and was effectively restored by azilsartan; (3) anomalies in the expression levels of monocyte chemotactic protein 1 (MCP1), F4/80, NAD(P)H oxidase (Nox) 2, and Nox4 of the aortic wall and in the expression of TNFα in the perivascular fat were strongly attenuated by azilsartan compared to candesartan cilexetil. Conclusions: These results provide evidence that azilsartan prevents endothelial dysfunction in diabetic mice, more potently than does candesartan cilexetil. Azilsartan’s higher affinity for and slower dissociation from AT1 receptors may underlie its efficacy in diabetic vascular dysfunction via a dual effect on uncoupled eNOS and on Nox. |
|||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||
| 主題 | Telmisartan | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||
| 主題 | Olmesartan | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||
| 主題 | Candesartan Cilexetil | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||
| 主題 | Insulin Tolerance Test | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||
| 主題 | Reactive Oxidant Species | |||||||||||||||||||||||
| 書誌情報 |
en : Cardiovascular Diabetology 巻 13, p. 30, 発行日 2014-01-31 |
|||||||||||||||||||||||
| 収録物ID | ||||||||||||||||||||||||
| 収録物識別子タイプ | EISSN | |||||||||||||||||||||||
| 収録物識別子 | 14752840 | |||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||
| 出版者 | BioMed Central | |||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||
| 出版者 | Springer Nature | |||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 権利情報 | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | |||||||||||||||||||||||
| EID | ||||||||||||||||||||||||
| 識別子 | 274562 | |||||||||||||||||||||||
| 識別子タイプ | URI | |||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||
